Your session is about to expire
← Back to Search
Special Diet for Kidney Stones Post-Bariatric Surgery
N/A
Recruiting
Led By Prochaska Megan, MD
Research Sponsored by University of Chicago
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Participants pre-bariatric surgery who are approved and planned for surgery in the Bariatric Surgery Center at University of Chicago Medicine.
Be older than 18 years old
Must not have
Patients with primary renal diseases or renal impairment (eGFR < 90)
Patients with known bladder voiding problems
Timeline
Screening 3 weeks
Treatment Varies
Follow Up multiple times over approximately 13 months (a. at the start [approximately 1 month prior to surgery] b. about 2 months in [approximately 1 month after surgery] and c. at the end [approximately 13 months from start])
Awards & highlights
No Placebo-Only Group
Summary
This trial is investigating how diet and sex affect the risk of kidney stones in people who have had gastric bypass surgery.
Who is the study for?
This trial is for individuals approved for bariatric surgery at the University of Chicago Medicine, who have no personal or family history of kidney stones. It's not open to those with vitamin D deficiency (levels below 25ng/mL), primary renal diseases, impaired kidney function (eGFR < 90), or known bladder voiding issues.
What is being tested?
The study investigates how a special diet affects the risk of developing kidney stones after gastric bypass surgery. Participants will follow this clinic-provided diet for six days and attend three research clinic visits.
What are the potential side effects?
Since this trial involves following a special diet rather than medication, side effects may be minimal but could include digestive changes depending on individual tolerance to the dietary regimen.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am approved for and scheduled to have bariatric surgery at the University of Chicago Medicine.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
My kidney function is impaired.
Select...
I have issues emptying my bladder.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ multiple times over approximately 13 months (a. at the start [approximately 1 month prior to surgery] b. about 2 months in [approximately 1 month after surgery] and c. at the end [approximately 13 months from start])
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~multiple times over approximately 13 months (a. at the start [approximately 1 month prior to surgery] b. about 2 months in [approximately 1 month after surgery] and c. at the end [approximately 13 months from start])
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in urine calcium oxalate supersaturation over time
Secondary study objectives
Calcium
Oxalate
Urine citrate
+1 moreOther study objectives
Association of first and measures with GLP-1 (physiologic parameter)
Association of first and measures with glucagon (physiologic parameter)
Insulin
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Sleeve gastrectomy subjectsExperimental Treatment1 Intervention
Inclusion Criteria: Age 18-70. Participants pre-sleeve gastrectomy who are approved and sleeve gastrectomy in the Bariatric Surgery Center at the UCM.
Exclusion Criteria: Patients with primary kidney diseases, kidney stone disease, or kidney impairment (eGFR \< 90). Patients with known bladder voiding problems.
Participants will complete a diet record and a 24-hour urine collection both before and after surgery.
Participants will consume a 3 day fixed diet and present to the clinical research center for timed blood and urine draws. They will do this before and twice after (1 month and 1 year) surgery.
Group II: Roux-en-y gastric bypass subjectsExperimental Treatment1 Intervention
Inclusion Criteria: Age 18-70. Participants pre-Roux-en-y gastric bypass (RYGB) who are approved and planned for Roux-en-y gastric bypass surgery in the Bariatric Surgery Center at the UCM.
Exclusion Criteria: Patients with primary kidney diseases, kidney stone disease, or kidney impairment (eGFR \< 90). Patients with known bladder voiding problems.
Participants will complete a diet record and a 24-hour urine collection both before and after surgery.
Participants will consume a 3 day fixed diet and present to the clinical research center for timed blood and urine draws. They will do this before and twice after (1 month and 1 year) surgery.
Find a Location
Who is running the clinical trial?
University of ChicagoLead Sponsor
1,062 Previous Clinical Trials
840,108 Total Patients Enrolled
1 Trials studying Bariatric Surgery Candidates
30 Patients Enrolled for Bariatric Surgery Candidates
Prochaska Megan, MDPrincipal InvestigatorUniversity of Chicago
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My kidney function is impaired.You have never had kidney stones, and no one in your family has had kidney stones.I am approved for and scheduled to have bariatric surgery at the University of Chicago Medicine.I have issues emptying my bladder.Your blood test shows that you have very low levels of vitamin D.
Research Study Groups:
This trial has the following groups:- Group 1: Roux-en-y gastric bypass subjects
- Group 2: Sleeve gastrectomy subjects
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.